Amplifon AMP.MI
Amplifon is a global distributor of hearing solutions, operating a network of clinics and audiology centers that sell hearing aids and hearing care services to clients with hearing loss. Amplifon, with a forward P/E of 13.65 and an FCF yield of 11.10%, presents an attractive valuation that does not fully discount the growth potential of the GN Hearing acquisition, although high leverage (ND/EBITDA 3.09) and low ROE (5.74) are counterweights.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Amplifon is a global distributor of hearing solutions, operating a network of clinics and audiology centers that sell hearing aids and hearing care services to clients with hearing loss. Amplifon, with a forward P/E of 13.65 and an FCF yield of 11.10%, presents an attractive valuation that does not fully discount the growth potential of the GN Hearing acquisition, although high leverage (ND/EBITDA 3.09) and low ROE (5.74) are counterweights.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.1 |
| Quality / Moat | 4.8 |
| Valuation | 7.0 |
| Growth | 5.7 |
| Dividend | 4.2 |
| Momentum | 2.7 |
| Risk & Context | 3.5 |
OVERALL SCORE: 4.9/10
Context and risks
Italy presents an elevated governance risk, with weak minority protection and legal uncertainty, which justifies an additional penalty on the base risk. The GN Hearing acquisition adds integration and increased leverage risk.
News considered in the analysis
- Amplifon to acquire GN Hearing in $2.6bn deal — Adquisición transformadora que redefine el panorama competitivo y el perfil de crecimiento, aunque añade riesgo de integración y apalancamiento.
- Amplifon’s Big Bet Has Investors Hearing Alarm Bells — El mercado muestra escepticismo sobre la operación GN Hearing, reflejado en el mal momentum de la acción.
- Amplifon GN Hearing Deal Reshapes Valuation And Growth Outlook — La operación mejora las perspectivas de crecimiento a largo plazo, pero la valoración resultante es incierta.
- Is Amplifon (AMFPF) Stock Undervalued Right Now? — Artículo genérico de análisis de valoración sin información nueva.
- European Value Picks: 3 Stocks Trading At An Estimated Discount — Listículo sin información específica accionable.
Verdict: Hold, with attention to the evolution of the GN Hearing integration and the resulting leverage.
Main risk: The main risk is the integration of GN Hearing and the increase in leverage, which could pressure financial health and the dividend if the operation does not generate the expected synergies.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →